Description
Cagrilintide and Semaglutide is a research peptide combination of a long-acting amylin analog and a GLP-1 receptor analog, supplied as a high-purity lyophilized blend for laboratory use only.
Cagrilintide is a modified 37-amino-acid amylin analog featuring structural substitutions and a fatty-acid side chain. Semaglutide is a synthetic GLP-1 analog with a C18 fatty-diacid modification. Together they are used in controlled laboratory studies of peptide identity, stability, structure, and related biochemical pathways. Each component is typically verified by HPLC and mass spectrometry.
In laboratory and preclinical research, this pairing has been investigated for effects on metabolic and neuroendocrine signaling, including amylin-receptor models, GLP-1 pathway activity, appetite-regulation mechanisms, and energy-balance pathways in experimental systems. These findings are limited to research settings and do not establish approved medical use.
This material is not approved for human or veterinary use and is not intended for consumption.
Reviews
There are no reviews yet.